These results suggest that, where clinically appropriate, tirzepatide or semaglutide may be preferable to liraglutide or DPP4 inhibitors in patients with T2D at risk of liver disease progression, particularly given the presence of MASLD with accompanying hepatic fibrosis. The gene discussed is DPP4; the disease is metabolic dysfunction-associated steatotic liver disease.